Ruxolitinib + Placebo
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 37/100
37
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
MPN (Myeloproliferative Neoplasms)
Conditions
MPN (Myeloproliferative Neoplasms)
Trial Timeline
Aug 1, 2009 → Oct 1, 2015
NCT ID
NCT00952289About Ruxolitinib + Placebo
Ruxolitinib + Placebo is a phase 3 stage product being developed by Incyte for MPN (Myeloproliferative Neoplasms). The current trial status is completed. This product is registered under clinical trial identifier NCT00952289. Target conditions include MPN (Myeloproliferative Neoplasms).
Hype Score Breakdown
Clinical
17
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00952289 | Phase 3 | Completed |
Competing Products
6 competing products in MPN (Myeloproliferative Neoplasms)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Ruxolitinib | Incyte | Phase 2 | 32 |
| Parsaclisib + Parsaclisib + Ruxolitinib + Parsaclisib + Parsaclisib | Incyte | Phase 2 | 24 |
| Ruxolitinib + Anagrelide + Placebo + Placebo | Incyte | Phase 2 | 24 |
| itacitinib | Incyte | Phase 2 | 32 |
| Pemigatinib | Incyte | Phase 2 | 32 |
| Itacitinib + Ruxolitinib | Incyte | Phase 2 | 32 |